SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
Open original sourceLoading market dashboard
Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
Open original source